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We reported an efficient route for the synthesis of pyrazole clubbed imidazolone compounds. The products were 
characterized by standard techniques like IR,1H and 13C NMR, and LC-MS. They were investigated for their antimicrobial 
activity against several strains of bacteria (E. coli, P. aeruginosa, S. aureus and S. pyogenes) and fungi  
(C. albicans, A. niger,andA. clavatus) using broth dilution method. Compounds3j (-2-NO2),3r (-4-Br), and 3i (-2-OCH3) 
showed significant antimicrobial activity. 
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Increasing the level of antimicrobial resistance makes 
surveillance difficult for human beings at a global level. 
Inadequate doses and self-medication make the 
traditional approaches worthless. This critical issue can 
only be solved by the research of new and effective 
antimicrobials. Our research group is focused on the last 
couple of decades for the synthesis of heterocyclic base 
antimicrobial agents
1-5
. In continuation, we have 
synthesized new pyrazole clubbed imidazolone 
heterocyclic compounds and screened for their 
antimicrobial activity. It is well known that hybrid 
molecules show very good activity
6-10
 and therefore in 
this paper we attempted to synthesize pyrazole clubbed 
imidazole compounds. 
 
Results and Discussion 
In the present work, we studied the reaction of imines 
2a-t with glycine (Scheme I). 3-(4-Nitrophenyl)-1-
phenyl-1H-pyrazole-4-carbaldehyde 1 was stirred at RT 
with different derivatives of aniline. This reaction 
generated imines 1-(3-(4-nitrophenyl)-1-phenyl-1H-
pyrazol-4-yl)-N-substituted phenylmethanimines2a-t. 
This was further reacted with glycine in the presence of 





Antimicrobial activity was accomplished by Mueller 
Hinton Broth dilution method (Becton Dickinson, 
USA)11,12. The strains were acquired from CSIR-
IMTECH, Chandigarh, India. Antibacterial activity was 
screened in triple sets at diverse concentrations of 1000, 
500, 250 and 200 µg/mL. The compounds which were 
found to be active in primary analysis were further 
diluted and evaluated. 10 µg/mL suspensions were 
further injected on appropriate media and the growth 
was noted after one or two days. In antifungal 
evaluation, primary screening was carried out in six sets 
at different concentrations of 1000, 500, and 250 µg/mL. 
The compounds found active were similarly diluted to 
200, 125, 100, 62.5, 50, 25, and 12.5 µg/mL 
concentrations for a secondary screening. Minimum 
Inhibitory Concentration (MIC) is the lowest 
concentration of compound at which no growth of 
microbes could be detected after spot subculture for each 
compound. In this study, Ciprofloxacin and 
Nystatinwere the standard drugs for evaluating the 
antibacterial activity and antifungal activity respectively. 
 
Discussion on antibacterial and antifungal activities 
Antimicrobial activity data are as shown in Table I. 
A few compounds showed a minimum inhibitory 
concentration (MIC) value less than the standard drug. 
While some compounds showed the values comparable 
to the standard drug. Compound 3r showed excellent 
activity against E. coli at MIC 12.5 µg/mL. Compound 
3j was the most active against P. aeruginosa. Results 
of antifungal activity showed that compound 3i gave 
12.5 µg/mL MIC value against A. niger. The standard 
drug used was Ciprofloxacin and Nystatin for 
















4-yl)-N-substituted phenylmethanimines, 2a-t 
A mixture of 3-(4-nitrophenyl)-1-phenyl-1H-
pyrazole-4-carbaldehyde 1 (0.01 mol) and substituted 
aniline (0.01 mol) was continuously stirred in methanol 
(10 mL) for 2-3 h at RT. Product was filtered off, 
washed with aqueous methanolic solution and 





Compounds 2a-t (0.01 mol) were taken in a round 
bottom flask having tetrahydrofuran (THF) (15 mL) as a 
solvent. Then solution of glycine (0.02 mol) (in distilled 
water) was added and refluxed for 24 h. This reaction 
mixture was poured into crushed ice to obtain the 
product which was filtered and washed with hot water to 
 
 
Scheme I — Synthetic pathway of the newly synthesized compounds 
 
Table I — Results of biological activities of compounds 3a-t 
Compd -R 
Minimum inhibitory concentrations for 
bacteria(MICB) in µg/mL 
 
Minimum inhibitory concentrations for fungi 
(MICF) in µg/mL 
E. c. P. a. S. a. S. p. C. a. A. n. A. c. 
3a -H 200 100 100 125 1000 250 500 
3b -2-F 62.5 125 500 500 >1000 500 500 
3c -4-F 125 200 250 25 >1000 >1000 >1000 
3d -2-CH3 200 125 200 200 500 100 1000 
3e -3-CH3 100 200 250 250 1000 200 >1000 
3f -4-CH3 250 250 500 500 100 1000 50 
3g -2-OCH3 100 100 500 500 1000 1000 1000 
3h -3-OCH3 200 250 100 200 >1000 1000 1000 
3i -4-OCH3 100 125 200 200 500 12.5 1000 
3j -2- NO2 200 12.5 100 100 1000 250 250 
3k -3-NO2 250 200 125 125 1000 500 500 
3l -4-NO2 250 250 200 250 1000 1000 1000 
3m -2-Cl 125 125 250 250 >1000 1000 1000 
3n -3-Cl 125 125 200 200 1000 >1000 >1000 
3o -4-Cl 200 50 200 200 500 1000 1000 
3p -2-Br 250 200 500 500 500 1000 1000 
3q -3-Br 100 200 250 250 250 >1000 >1000 
3r -4-Br 12.5 125 250 100 1000 >1000 >1000 
3s -4-Br-2-CH3 250 200 200 200 1000 100 1000 
3t -3-Cl-4-F 250 200 250 250 1000 500 500 
Ciprofloxacin 25 25 50 50 ─ ─ ─ 
Nystatin ─ ─ ─ ─ 100 100 100 
E. c. - Escherichia coli, P. a. - Pseudomonas aeruginosa, S. a. - Staphylococcus aureus, S. p. - Streptococcus pyogenes; C.a. - Candida 
albicans, A. n.- Aspergillusniger, A. c. - Aspergillusclavatus. 
 




remove excess of reactant, followed by recrystallization 
from ethanol (95%). All the synthesized compounds 
were prepared using the same method. 
2-(3-(4-Nitrophenyl)-1-phenyl-1H-pyrazol-4-yl)-
3-phenylimidazolidin-4-one,3a: 69%. m.p.187-
189°C. IR (KBr): 1641 (C=O stretching, imidazolone 
ring (-C(=O)-N<)), 1514, 1575 (-N-H 
bending,imidazolone ring (>NH)), 1456 (-C-H 
bending,imidazolone ring (>CH2)), 1387, 1523 (-N=O 
stretching, -NO2 group), 1294 (-C-N 
stretching,imidazolone ring (>NH)), 965 (-C-H bending, 
aromatic ring), 821 cm
−1
 (-C-H bending, pyrazole ring 
(>C=C(H)N)); 
1
H NMR (400 MHz, CDCl3): δ 3.41 dd 
(1H,H-C-H), 3.52 dd (1H, H-C-H), 6.05 s (1H, -CH of 
imidazolone ring), 7.15-8.29 m (14H,Ar-H), 7.67 s (1H, 
-CH of pyrazole ring), 7.93 s (1H, -NH of imidazolone 
ring); 13C NMR (100 MHz, CDCl3): δ 52.2, 73.2, 117.3, 
119.8 (2), 123.1, 124.5 (2), 126.3 (2), 126.5, 127.6 (2), 
128.1, 128.7 (2), 129.4 (2), 139.3, 139.8, 141.6, 147.7, 
149.8, 170.5; LC-MS: m/z 425.10 [M
+
]. Anal. Calcd for: 
C24H19N5O3: C, 67.76; H, 4.50; N, 16.46. Found: C, 
67.75; H, 4.52; N, 16.45%. 
3-(2-Fluorophenyl)-2-(3-(4-nitrophenyl)-1-phenyl-
1H-pyrazol-4-yl)imidazolidin-4-one, 3b: 65%. 
m.p.137-139°C. IR (KBr): 1652 (C=O stretching, 
imidazolone ring (-C(=O)-N<)), 1516, 1569 (-N-H 
bending, imidazolone ring (>NH)), 1463 (-C-H 
bending, imidazolone ring (>CH2)), 1352, 1526 (-N=O 
stretching, -NO2 group), 1354 (-C-N stretching, 
imidazolone ring (>NH)), 1078 (-C-F stretching, -F 
group), 972 (-C-H bending, aromatic ring), 847 cm
−1
 
(-C-H bending, pyrazole ring (>C=C(H)N)); 
1
H NMR 
(400 MHz, CDCl3): δ 3.46 dd (1H, H-C-H), 3.53 dd 
(1H, H-C-H), 6.03 s (1H, -CH of imidazolone ring), 
7.12-8.30 m (13H, Ar-H), 7.64 s (1H, -CH of pyrazole 
ring), 7.87 s (1H, -NH of imidazolone ring); 
13
C NMR 
(100 MHz, CDCl3): δ 52.3, 73.3, 115.6, 117.4, 119.7 
(2), 123.1, 123.4, 124.6 (2), 124.7, 126.1 (2), 126.4, 
127.6, 129.2, 129.5 (2), 139.2, 139.9, 147.8, 149.7, 
162.7, 170.3; LC-MS: m/z 443.26 [M
+
]. Anal. Calcd 
for: C24H18FN5O3: C, 65.01; H, 4.09; N, 15.79. Found: 
C, 65.02; H, 4.11; N, 15.81%. 
3-(4-Fluorophenyl)-2-(3-(4-nitrophenyl)-1-phenyl-
1H-pyrazol-4-yl)imidazolidin-4-one, 3c: 64%.  
m.p.160-162°C. IR (KBr): 1643 (C=O stretching, 
imidazolone ring (-C(=O)-N<)), 1512, 1557 (-N-H 
bending, imidazolone ring (>NH)), 1453 (-C-H bending, 
imidazolone ring (>CH2)), 1346, 1532 (-N=O stretching, 
-NO2 group), 1293 (-C-N stretching, imidazolone ring 
(>NH)), 1053 (-C-F stretching, -F group), 971 (-C-H 
bending, aromatic ring), 796 cm
−1
 (-C-H bending, 
pyrazole ring (>C=C(H)N)); 
1
H NMR (400 MHz, 
CDCl3): δ 3.42 dd (1H, H-C-H), 3.56 dd (1H, H-C-H), 
6.02 s (1H, -CH of imidazolone ring), 7.13-8.21 m (13H, 
Ar-H), 7.64 s (1H, -CH of pyrazole ring), 7.92 s (1H, -
NH of imidazolone ring); 
13
C NMR (100 MHz, CDCl3): 
δ 52.0, 73.5, 115.6 (2), 117.4, 119.7 (2), 123.1, 123.3 
(2), 124.4 (2), 126.5 (3), 129.4 (2), 137.4, 139.2, 139.8, 
147.7, 150.1, 162.7, 170.5; LC-MS: m/z 443.08 [M+]. 
Anal. Calcd for: C24H18FN5O3: C, 65.01; H, 4.09; N, 




193°C. IR (KBr): 1647 (C=O stretching, imidazolone 
ring (-C(=O)-N<)), 1509, 1576 (-N-H bending, 
imidazolone ring (>NH)), 1476 (-C-H bending, 
imidazolone ring (>CH2)), 1392 (-C-H bending, -CH3 
group), 1350, 1522 (-N=O stretching, -NO2 group), 
1285 (-C-N stretching, imidazolone ring (>NH)), 971  
(-C-H bending, aromatic ring), 825 cm
−1
 (-C-H 
bending, pyrazole ring (>C=C(H)N)); 1H NMR (400 
MHz, CDCl3): δ 2.07 s (1H, -CH3), 3.43 dd (1H, H-C-
H), 3.55 dd (1H, H-C-H), 6.03 s (1H, -CH of 
imidazolone ring), 6.84-8.27 m (13H, Ar-H), 7.61 s 
(1H, -CH of pyrazole ring), 7.94 s (1H, -NH of 
imidazolone ring); 13C NMR (100 MHz, CDCl3): δ 
17.5, 52.3, 73.6, 116.7, 117.3, 120.2 (2), 123.1, 124.5 
(2), 125.8, 126.3 (2), 126.4, 129.5 (3), 130.6, 134.2, 
138.8, 139.2, 139.9, 147.8, 149.7, 170.3; LC-MS: m/z 
439.28 [M
+
]. Anal. Calcd for: C25H21N5O3: C, 68.33; 




3-(m-tolyl)imidazolidin-4-one, 3e: 72%. m.p.111-
113°C. IR (KBr): 1648 (C=O stretching, imidazolone 
ring (-C(=O)-N<)), 1517, 1576 (-N-H bending, 
imidazolone ring (>NH)), 1456 (-C-H bending, 
imidazolone ring (>CH2)), 1395 (-C-H bending, -CH3 
group), 1345, 1536 (-N=O stretching, -NO2 group), 
1297 (-C-N stretching, imidazolone ring (>NH)), 967  
(-C-H bending, aromatic ring), 808 cm
−1
 (-C-H 
bending, pyrazole ring (>C=C(H)N)); 
1
H NMR (400 
MHz, CDCl3): δ 2.24 s (3H, -CH3), 3.41 dd (1H, H-C-
H), 3.55 dd(1H, H-C-H), 6.04 s (1H, -CH of 
imidazolone ring), 7.17-8.28 m (13H, Ar-H), 7.66 s 
(1H, -CH of pyrazole ring), 7.88 s (1H, -NH of 
imidazolone ring); 
13
C NMR (100 MHz, CDCl3): δ 
21.4, 52.1, 73.5, 117.3, 119.7 (2), 121.4, 123.2, 124.5 
(2), 124.6, 124.8, 126.1 (2), 126.3, 128.7, 129.4 (2), 
138.5, 139.3, 139.8, 141.7, 147.8, 149.9, 170.5;  




LC-MS: m/z 439.19 [M
+
]. Anal. Calcd for: 
C25H21N5O3: C, 68.33; H, 4.82; N, 15.94. Found: C, 
68.36; H, 4.83; N, 15.99%. 
 
2-(3-(4-Nitrophenyl)-1-phenyl-1H-pyrazol-4-yl)-
3-(p-tolyl)imidazolidin-4-one, 3f: 59%. m.p.156-
158°C IR (KBr): 1657 (C=O stretching, imidazolone 
ring (-C(=O)-N<)), 1523, 1578 (-N-H bending, 
imidazolone ring (>NH)), 1469 (-C-H bending, 
imidazolone ring (>CH2)), 1391 (-C-H bending, -CH3 
group), 1342, 1516 (-N=O stretching, -NO2 group), 
1293 (-C-N stretching, imidazolone ring (>NH)), 982  
(-C-H bending, aromatic ring), 798 cm
−1
 (-C-H 
bending, pyrazole ring (>C=C(H)N)); 1H NMR (400 
MHz, CDCl3): δ 2.30 s (3H, -CH3), 3.45 dd (1H, H-C-
H), 3.58 dd (1H, H-C-H), 6.00 s (1H, -CH of 
imidazolone ring), 6.93-8.27 m (13H, Ar-H), 7.68 s 
(1H, -CH of pyrazole ring), 7.94 s (1H, -NH of 
imidazolone ring); 13C NMR (100 MHz, CDCl3): δ 
21.2, 52.0, 73.5, 117.4, 119.7 (2), 123.1, 124.5 (2), 
126.3 (3), 129.3 (2), 129.5 (2), 133.5, 136.7, 138.6, 
139.2, 147.8, 150.1, 170.6; LC-MS: m/z 439.05 [M
+
]. 
Anal. Calcd for: C25H21N5O3: C, 68.33; H, 4.82; N, 




60%. m.p.151-153°C. IR (KBr): 1645 (C=O 
stretching,imidazolone ring (-C(=O)-N<)), 1539, 1564 
(-N-H bending,imidazolone ring (>NH)), 1463 (-C-H 
bending,imidazolone ring (>CH2)), 1345, 1536 (-N=O 
stretching, -NO2 group), 1326 (-C-N 
stretching,imidazolone ring (>NH)), 1030, 1254  
(-C-O-C stretching, -OCH3 group), 967 (-C-H bending, 
aromatic ring), 859 cm
−1
 (-C-H bending, pyrazole ring 
(>C=C(H)N)); 
1
H NMR (400 MHz, CDCl3): δ 3.43 dd 
(1H, H-C-H), 3.55 dd (1H, H-C-H), 3.84 s (3H, -
OCH3), 6.03 s (1H, -CH of imidazolone ring),  
6.98-8.29 m (13H, Ar-H), 7.64 s (1H, -CH of pyrazole 
ring), 7.90 s (1H, -NH of imidazolone ring); 
13
C NMR 
(100 MHz, CDCl3): δ 52.3, 55.9, 73.6, 112.7, 117.2, 
117.3, 119.9 (2), 121.3, 124.5 (2), 126.3 (3), 128.3, 
128.9, 129.4 (2), 139.2, 139.6, 147.8, 149.8, 162.1, 
170.5; LC-MS: m/z 455.32 [M+]. Anal. Calcd for: 
C25H21N5O4: C, 65.93; H, 4.65; N, 15.38. Found: C, 




62%. m.p.109-111°C. IR (KBr): 1653 (C=O stretching, 
imidazolone ring (-C(=O)-N<)), 1523, 1570 (-N-H 
bending, imidazolone ring (>NH)), 1467 (-C-H 
bending, imidazolone ring (>CH2)), 1352, 1539 (-N=O 
stretching, -NO2 group), 1328 (-C-N stretching, 
imidazolone ring (>NH)), 1063, 1241 (-C-O-C 
stretching, -OCH3 group), 971 (-C-H bending, aromatic 
ring), 836 cm
−1
 (-C-H bending, pyrazole ring 
(>C=C(H)N)); 
1
H NMR (400 MHz, CDCl3): δ 3.42 dd 
(1H, H-C-H), 3.52 dd (1H, H-C-H), 3.72 s (3H, -
OCH3), 6.04 s (1H, -CH of imidazolone ring), 6.83-
8.27 m (13H, Ar-H), 7.66 s (1H, -CH of pyrazole ring), 
7.91 s (1H, -NH of imidazolone ring); 13C NMR (100 
MHz, CDCl3): δ 52.0, 55.6, 73.5, 116.3, 117.0, 119.6, 
119.7 (2), 123.2, 124.3, 124.5 (2), 125.6, 126.2 (3), 
129.4 (2), 139.3, 139.8, 142.6, 147.8, 150.2, 160.7, 
170.2; LC-MS: m/z 455.20 [M
+
]. Anal. Calcd for: 
C25H21N5O4: C, 65.93; H, 4.65; N, 15.38. Found: C, 




69%. m.p.99-101°C. IR (KBr): 1654 (C=O 
stretching,imidazolone ring (-C(=O)-N<)), 1511, 1563 
(-N-H bending,imidazolone ring (>NH)), 1456 (-C-H 
bending,imidazolone ring (>CH2)), 1352, 1530 (-N=O 
stretching, -NO2 group), 1290 (-C-N 
stretching,imidazolone ring (>NH)), 1024, 1264 (-C-
O-C stretching, -OCH3 group), 973 (-C-H bending, 
aromatic ring), 839cm
−1
 (-C-H bending, pyrazole ring 
(>C=C(H)N)); 
1
H NMR (400 MHz, CDCl3): δ 3.40 dd 
(1H,H-C-H), 3.55 dd (1H, H-C-H), 3.80 s (3H, -
OCH3),6.03 s (1H, -CH of imidazolone ring), 6.94-
8.21 m (13H,Ar-H), 7.66 s (1H, -CH of pyrazole 
ring), 7.94 s (1H, -NH of imidazolone ring); 
13
C NMR 
(100 MHz, CDCl3): δ 52.3, 55.7, 73.5, 114.3 (2), 
117.3, 119.7 (2), 122.5 (2), 123.4, 124.5 (2), 126.1 
(3), 129.4 (2), 134.1, 139.2, 139.6, 147.8, 149.7, 
158.8, 170.3; LC-MS: m/z 455.41 [M
+
]. Anal. Calcd 
for: C25H21N5O4:C, 65.93; H, 4.65; N, 15.38. Found: 




m.p.103-105°C. IR (KBr): 1648 (C=O 
stretching,imidazolone ring (-C(=O)-N<)), 1520, 1578 
(-N-H bending,imidazolone ring (>NH)), 1456 (-C-H 
bending,imidazolone ring (>CH2)), 1356, 1532 (-N=O 
stretching, -NO2 group), 1295 (-C-N 
stretching,imidazolone ring (>NH)), 968 (-C-H 
bending, aromatic ring), 802cm
−1
 (-C-H bending, 
pyrazole ring (>C=C(H)N)); 
1
H NMR (400 MHz, 
CDCl3): δ 3.45 dd (1H,H-C-H), 3.50 dd (1H, H-C-H), 
6.03 s (1H, -CH of imidazolone ring), 7.45-8.31 m 
(13H,Ar-H), 7.68 s (1H, -CH of pyrazole ring), 7.92 s 
(1H, -NH of imidazolone ring); 
13
C NMR (100 MHz, 




CDCl3): δ 52.1, 72.2, 113.4, 117.4, 120.2 (2), 123.2, 
124.5 (2), 125.3, 125.6, 126.3 (3), 129.4 (2), 136.7, 
137.8, 139.0, 139.8, 142.5, 147.8, 149.7, 170.6; LC-
MS: m/z 470.15 [M
+
]. Anal. Calcd for: C24H18N6O5:C, 





m.p.172-174°C. IR (KBr): 1650 (C=O 
stretching,imidazolone ring (-C(=O)-N<)), 1536, 1562 
(-N-H bending,imidazolone ring (>NH)), 1465 (-C-H 
bending,imidazolone ring (>CH2)), 1346, 1342 (-N=O 
stretching, -NO2 group), 1324 (-C-N stretching, 
imidazolone ring (>NH)), 974 (-C-H bending, 
aromatic ring), 821cm
−1
 (-C-H bending, pyrazole ring 
(>C=C(H)N)); 
1
H NMR (400 MHz, CDCl3): δ 3.43 dd 
(1H,H-C-H), 3.54 dd (1H, H-C-H), 6.02 s (1H, -CH 
of imidazolone ring), 7.45-8.25 m (13H,Ar-H), 7.67 s 
(1H, -CH of pyrazole ring), 7.90 s (1H, -NH of 
imidazolone ring); 
13
C NMR (100 MHz,CDCl3): δ 
52.3, 73.4, 117.3, 119.6, 119.8 (2), 123.2, 124.5 (2), 
126.0 (3), 129.4 (2), 129.9, 133.4, 139.3, 139.9, 
142.5, 147.8, 148.3, 149.8, 170.2; LC-MS: m/z 470.73 
[M
+
]. Anal. Calcd for: C24H18N6O5:C, 61.27; H, 3.86; 




m.p.110-112°C. IR (KBr): 1649 (C=O 
stretching,imidazolone ring (-C(=O)-N<)), 1526, 1547 
(-N-H bending,imidazolone ring (>NH)), 1460 (-C-H 
bending,imidazolone ring (>CH2)), 1342, 1536  
(-N=O stretching, -NO2 group), 1347 (-C-N 
stretching,imidazolone ring (>NH)), 973 (-C-H 
bending, aromatic ring), 799cm
−1
 (-C-H bending, 
pyrazole ring (>C=C(H)N)); 
1
H NMR (400 MHz, 
CDCl3): δ 3.45 dd (1H,H-C-H), 3.56 dd (1H, H-C-H), 
6.04 s (1H, -CH of imidazolone ring), 6.97-8.24 m 
(13H,Ar-H), 7.63 s (1H, -CH of pyrazole ring), 7.91 s 
(1H, -NH of imidazolone ring); 
13
C NMR (100 MHz, 
CDCl3): δ 52.0, 73.5, 117.2, 119.7 (2), 123.3, 124.2 
(2), 124.5 (2), 126.3 (3), 129.4 (2), 131.3 (2), 139.2, 
139.8, 143.6, 147.8, 147.7, 148.1, 149.7, 170.3; LC-
MS: m/z 470.52 [M
+
]. Anal. Calcd for: C24H18N6O5:C, 




1H-pyrazol-4-yl)imidazolidin-4-one, 3m: 68%. 
m.p.149-151°C. IR (KBr): 1653 (C=O stretching, 
imidazolone ring (-C(=O)-N<)), 1521, 1545 (-N-H 
bending, imidazolone ring (>NH)), 1458 (-C-H 
bending, imidazolone ring (>CH2)), 1347, 1526 (-N=O 
stretching, -NO2 group), 1332 (-C-N stretching, 
imidazolone ring (>NH)), 973 (-C-H bending, aromatic 
ring), 825 (-C-H bending, pyrazole ring (>C=C(H)N)), 
741 cm
−1
 (-C-Cl stretching, -Cl group); 
1
H NMR (400 
MHz, CDCl3): δ 3.43 dd (1H, H-C-H), 3.54 dd (1H, H-
C-H), 6.02 s (1H, -CH of imidazolone ring), 7.19-8.27 
m (13H, Ar-H), 7.64 s (1H, -CH of pyrazole ring), 7.92 
s (1H, -NH of imidazolone ring); 13C NMR (100 MHz, 
CDCl3): δ 52.3, 72.8, 117.3, 120.2 (2), 123.3 (2), 124.5 
(2), 126.5 (3), 127.2, 129.4 (2), 130.3, 131.1, 139.2, 
139.9, 140.3, 141.1, 147.8, 150.2, 170.2; LC-MS: m/z 
459.62 [M
+
]. Anal. Calcd for: C24H18ClN5O3: C, 62.68; 
H, 3.95; N, 15.23. Found: C, 62.71; H, 3.93; N, 
15.20%. 
3-(3-Chlorophenyl)-2-(3-(4-nitrophenyl)-1-phenyl-
1H-pyrazol-4-yl)imidazolidin-4-one, 3n: 70%. 
m.p.120-122°C. IR (KBr): 1653 (C=O 
stretching,imidazolone ring (-C(=O)-N<)), 1513, 1569 
(-N-H bending,imidazolone ring (>NH)), 1463 (-C-H 
bending,imidazolone ring (>CH2)), 708 (-C-Cl 
stretching, -Cl group), 1348, 1530 (-N=O stretching, -
NO2 group), 1287 (-C-N stretching,imidazolone ring 
(>NH)), 965 (-C-H bending, aromatic ring), 831cm−1 
(-C-H bending, pyrazole ring (>C=C(H)N)); 
1
H NMR 
(400 MHz, CDCl3): δ 3.45 dd (1H,H-C-H), 3.56 dd 
(1H, H-C-H), 6.02 s (1H, -CH of imidazolone ring), 
7.20-8.27 m (13H,Ar-H), 7.66 s (1H, -CH of pyrazole 
ring), 7.91 s (1H, -NH of imidazolone ring); 
13
C NMR 
(100 MHz, CDCl3): δ 52.0, 73.5, 117.3, 119.7 (2), 
123.1, 124.5 (2), 125.7, 126.2 (2), 126.4, 127.8, 129.4 
(2), 130.4, 134.6, 135.9, 139.3, 139.6, 143.3, 147.8, 
149.7, 170.6; LC-MS: m/z 459.27 [M
+
]. Anal. Calcd 
for: C24H18ClN5O3:C, 62.68; H, 3.95; N, 15.23. 
Found: C, 62.66; H, 3.97; N, 15.25%. 
3-(4-Chlorophenyl)-2-(3-(4-nitrophenyl)-1-phenyl-
1H-pyrazol-4-yl)imidazolidin-4-one, 3o: 72%. 
m.p.157-159°C. IR (KBr): 1647 (C=O stretching, 
imidazolone ring (-C(=O)-N<)), 1518, 1564 (-N-H 
bending, imidazolone ring (>NH)), 1459 (-C-H 
bending, imidazolone ring (>CH2)), 1348, 1526 (-N=O 
stretching, -NO2 group), 1297 (-C-N stretching, 
imidazolone ring (>NH)), 973 (-C-H bending, aromatic 
ring), 829 (-C-H bending, pyrazole ring (>C=C(H)N)), 
796 cm−1 (-C-Cl stretching, -Cl group); 1H NMR (400 
MHz, CDCl3): δ 3.43 dd (1H, H-C-H), 3.54 dd (1H, H-
C-H), 6.00 s (1H, -CH of imidazolone ring), 7.34-8.24 
m (13H, Ar-H), 7.62 s (1H, -CH of pyrazole ring), 7.89 
s (1H, -NH of imidazolone ring); 
13
C NMR (100 MHz, 
CDCl3): δ 51.9, 73.6, 117.3, 119.7 (2), 123.1, 124.5 (2), 




125.7 (2), 126.3 (3), 129.1 (2), 129.4 (2), 133.4, 139.2, 
139.9, 140.1, 148.2, 149.9, 170.5. LC-MS: m/z 459.13 
[M
+
]. Anal. Calcd for: C24H18ClN5O3: C, 62.68; H, 
3.95; N, 15.23. Found: C, 62.70; H, 3.94; N, 15.21%. 
3-(2-Bromophenyl)-2-(3-(4-nitrophenyl)-1-phenyl-
1H-pyrazol-4-yl)imidazolidin-4-one, 3p: 69%. 
m.p.145-147°C. IR (KBr): 1648 (C=O 
stretching,imidazolone ring (-C(=O)-N<)), 1526, 1569 
(-N-H bending,imidazolone ring (>NH)), 1462 (-C-H 
bending,imidazolone ring (>CH2)), 1356, 1514 (-N=O 
stretching, -NO2 group), 1298 (-C-N 
stretching,imidazolone ring (>NH)), 968 (-C-H 
bending, aromatic ring), 829 (-C-H bending, pyrazole 
ring (>C=C(H)N)), 526cm
−1
 (-C-Br stretching, -Br 
group); 
1
H NMR (400 MHz, CDCl3): δ 3.42 dd 
(1H,H-C-H), 3.55 dd (1H, H-C-H), 5.99 s (1H, -CH 
of imidazolone ring), 7.11-8.26 m (13H,Ar-H), 7.64 s 
(1H, -CH of pyrazole ring), 7.91 s (1H, -NH of 
imidazolone ring); 
13
C NMR (100 MHz, CDCl3): δ 
52.3, 72.9, 117.4, 119.8 (2), 122.5, 123.2, 124.5 (2), 
126.3 (3), 127.8, 128.4, 129.2 (2), 131.7 (2), 139.2, 
139.8, 143.6, 147.7, 149.8, 170.6; LC-MS: m/z 502.89 
[M+]. Anal. Calcd for: C24H18BrN5O3:C, 57.16; H, 
3.60; N, 13.89. Found: C, 57.19; H, 3.62; N, 13.92%. 
3-(3-Bromophenyl)-2-(3-(4-nitrophenyl)-1-phenyl-
1H-pyrazol-4-yl)imidazolidin-4-one, 3q: 68%. 
m.p.126-128°C. IR (KBr): 1648 (C=O 
stretching,imidazolone ring (-C(=O)-N<)), 1521, 1567 
(-N-H bending,imidazolone ring (>NH)), 1456 (-C-H 
bending,imidazolone ring (>CH2)), 1342, 1526  
(-N=O stretching, -NO2 group), 1287 (-C-N 
stretching,imidazolone ring (>NH)), 967 (-C-H 
bending, aromatic ring), 821 (-C-H bending, pyrazole 
ring (>C=C(H)N)), 552cm
−1
 (-C-Br stretching, -Br 
group); 
1
H NMR (400 MHz, CDCl3): δ 3.41 dd 
(1H,H-C-H), 3.54 dd (1H, H-C-H), 6.03 s (1H, -CH 
of imidazolone ring), 7.10-8.27 m (13H,Ar-H), 7.64 s 
(1H, -CH of pyrazole ring), 7.91 s (1H, -NH of 
imidazolone ring); 
13
C NMR (100 MHz, CDCl3): δ 
52.1, 73.5, 117.4, 119.7 (2), 120.7, 123.2, 123.5, 
124.2 (2), 126.5 (3), 127.3, 129.5 (2), 130.1, 139.0, 
139.8, 143.7, 147.8, 149.9, 170.5; LC-MS: m/z 503.14 
[M
+
]. Anal. Calcd for: C24H18BrN5O3:C, 57.16; H, 
3.60; N, 13.89. Found: C, 57.18; H, 3.63; N, 13.88%. 
3-(4-Bromophenyl)-2-(3-(4-nitrophenyl)-1-phenyl-
1H-pyrazol-4-yl)imidazolidin-4-one, 3r:70%. 
m.p.173-175°C. IR (KBr): 1648 (C=O 
stretching,imidazolone ring (-C(=O)-N<)), 1512, 1547 
(-N-H bending,imidazolone ring (>NH)), 1468 (-C-H 
bending,imidazolone ring (>CH2)), 1345, 1536  
(-N=O stretching, -NO2 group), 1285 (-C-N 
stretching,imidazolone ring (>NH)), 969 (-C-H 
bending, aromatic ring), 830 (-C-H bending, pyrazole 
ring (>C=C(H)N)), 514cm
−1
 (-C-Br stretching, -Br 
group); 
1
H NMR (400 MHz, CDCl3): δ 3.44 dd 
(1H,H-C-H), 3.55 dd (1H, H-C-H), 6.03 s (1H, -CH 
of imidazolone ring), 7.43-8.25 m (13H,Ar-H), 7.63 s 
(1H, -CH of pyrazole ring), 7.91 s (1H, -NH of 
imidazolone ring); 13C NMR (100 MHz, CDCl3): δ 
52.0, 73.3, 117.3, 120.2 (2), 122.4, 123.2, 124.5 (2), 
126.3, 129.5 (2), 131.7 (2), 136.8 (2), 139.2, 139.9, 
140.5, 147.8, 149.7, 170.4; LC-MS: m/z 503.25 [M
+
]. 
Anal. Calcd for: C24H18BrN5O3:C, 57.16; H, 3.60; N, 
13.89. Found: C, 57.15; H, 3.58; N, 13.86%. 
3-(4-Bromo-2-methylphenyl)-2-(3-(4-nitrophenyl)-
1-phenyl-1H-pyrazol-4-yl)imidazolidin-4-one, 
3s:72%. m.p.194-196°C. IR (KBr): 1687 (C=O 
stretching, imidazolone ring (-C(=O)-N<)), 1502, 1598 
(-N-H bending, imidazolone ring (>NH)), 1454 (-C-H 
bending, imidazolone ring (>CH2)), 1392 (-C-H 
bending, -CH3 group), 1334, 1535 (-N=O stretching, -
NO2 group), 1294 (-C-N stretching, imidazolone ring 
(>NH)), 958 (-C-H bending, aromatic ring), 833 (-C-H 
bending, pyrazole ring (>C=C(H)N)), 547 cm−1 (-C-Br 
stretching, -Br group); 
1
H NMR (400 MHz, CDCl3): δ 
2.13 s (3H, -CH3), 3.43 dd (1H, H-C-H), 3.54 dd (1H, 
H-C-H), 6.02 s (1H, -CH of imidazolone ring), 7.05-
8.26 m (12H, Ar-H), 7.64 s (1H, -CH of pyrazole ring), 
7.92 s (1H, -NH of imidazolone ring); 13C NMR (100 
MHz, CDCl3): δ 16.8, 52.5, 73.6, 116.8, 117.4, 118.6, 
119.7 (2), 123.4, 124.6 (2), 126.3 (3), 129.3 (2), 133.1, 
134.2, 136.7, 137.7, 139.1, 139.8, 147.8, 149.9, 170.6. 
LC-MS: m/z 517.46 [M
+
]. Anal. Calcd for: 
C25H20BrN5O3: C, 57.93; H, 3.89; N, 13.51. Found: C, 
57.95; H, 3.87; N, 13.52%. 
3-(3-Chloro-4-fluorophenyl)-2-(3-(4-nitrophenyl)-
1-phenyl-1H-pyrazol-4-yl)imidazolidin-4-one, 3t: 
67%. m.p.184-186°C. IR (KBr):1647 (C=O 
stretching,imidazolone ring (-C(=O)-N<)), 1517, 1563 
(-N-H bending,imidazolone ring (>NH)), 1458 (-C-H 
bending,imidazolone ring (>CH2)), 1347, 1527  
(-N=O stretching, -NO2 group), 1287 (-C-N 
stretching, imidazolone ring (>NH)), 1078 (-C-F 
stretching, -F group), 965 (-C-H bending, aromatic 
ring), 823 (-C-H bending, pyrazole ring (>C=C(H)N)), 
741 cm
−1
 (-C-Cl stretching, -Cl group); 
1
H NMR  
(400 MHz, CDCl3): δ 3.46 dd (1H, H-C-H), 3.53 dd 
(1H, H-C-H), 6.02 s (1H, -CH of imidazolone ring), 
7.11-8.28 m (12H, Ar-H), 7.63 s (1H, -CH of pyrazole 
ring), 7.94 s (1H, -NH of imidazolone ring); 
13
C NMR 




(100 MHz, CDCl3): δ 52.3, 73.2, 113.5, 117.3, 119.7 
(2), 120.8, 121.4, 123.2, 123.7, 129.5 (2), 138.8, 139.3, 
147.8, 149.8, 154.3, 170.3; LC-MS: m/z 477.26 [M
+
]. 
Anal. Calcd for: C24H17ClFN5O3: C, 60.32; H, 3.59; N, 
14.66. Found: C, 60.30; H, 3.56; N, 14.63%. 
 
Conclusion 
We have revealed a concise and easy synthetic 
procedure for pyrazole and imidazolone derivatives. 
From the antimicrobial activity of the mentioned 
compounds, it may be concluded that compounds 3j  
(-2-NO2), 3r (-4-Br) and 3i (-2-OCH3) showed 
excellent antimicrobial activity. Additional research 
on biological profiles of these compounds is worth. 
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